시장보고서
상품코드
2108327

COVID-19 검출 키트 시장 분석 및 예측(-2035년) : 유형, 제품 유형, 기술, 구성 요소, 용도, 도입 형태, 최종 사용자, 이용 형태, 단계

COVID-19 Detection Kits Market Analysis and Forecast to 2035: Type, Product, Technology, Component, Application, Deployment, End User, Mode, Stage

발행일: | 리서치사: 구분자 Global Insight Services | 페이지 정보: 영문 350 Pages | 배송안내 : 3-5일 (영업일 기준)

    
    
    



가격
PDF & Excel (Single User License) help
PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 4,750 금액 안내 화살표 ₩ 6,690,000
PDF & Excel (Site License) help
PDF, Excel 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다.
US $ 5,750 금액 안내 화살표 ₩ 8,098,000
PDF & Excel (Enterprise License) help
PDF, Excel 보고서를 동일 기업의 전 세계 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF, Excel 이용 범위와 동일합니다.
US $ 6,750 금액 안내 화살표 ₩ 9,507,000
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 COVID-19 검출 키트 시장은 2025년 54억 달러에서 2035년까지 34억 달러로 확대되어 CAGR은―4.6%를 나타낼 것으로 예측됩니다. COVID-19 검출 키트 시장은 적당한 수준의 통합이 진행되고 있으며, PCR 기반 키트는 진단 정확도가 높아 확정 검사에 지속적으로 사용되고 있어 가장 큰 시장 점유율을 차지하고 있습니다. 한편, 신속 항원 검사 키트는 분산형 및 현장(Point-of-Care) 선별 검사에서 계속해서 널리 채택되고 있습니다. 수요는 호흡기 질환 감시, 다중 분자진단, 그리고 향후 감염병 유행에 대한 대비를 통해 점점 더 뒷받침되고 있습니다. 이 시장은 RT-PCR, 등온 증폭, 신속 면역 분석 기술 분야의 지속적인 혁신은 물론, 자동화된 검사 워크플로우 및 디지털 보고 시스템의 통합이 특징입니다. 또한 각 제조업체는 단일 검체로 여러 호흡기 병원체를 검출할 수 있는 다중 분석법의 확충에도 주력하고 있습니다. 예를 들어, 2025년 8월, 로슈(Roche)는 ‘cobas Respiratory 4-flex’ 분자진단 검사에 대해 미국 FDA의 510(k) 승인을 획득했습니다. 이 검사는 로슈의 TAGS 기술을 활용하여 SARS-CoV-2, A형 인플루엔자, B형 인플루엔자, RSV를 동시에 검출 및 감별하는 것으로, 단독 COVID-19 검사에서 종합적인 호흡기 질환 진단으로의 전환을 촉진함과 동시에 분자진단 시장의 혁신을 강화하고 있습니다.

유형별로는 2025년 COVID-19 검출 키트 시장에서 PCR 기반 키트 부문이 주도적인 위치를 차지했습니다. 이는 뛰어난 진단 정확도, 높은 민감도, 그리고 SARS-CoV-2 검출의 기준으로서 전 세계적으로 인정받고 있기 때문입니다. PCR 기반 키트는 확정 진단, 감시, 변이주 모니터링을 목적으로 병원, 진단실험실, 공중보건 검사실에서 계속해서 널리 사용되고 있습니다. 낮은 바이러스 부하 검출 능력, 다중 검사 지원, 규제 지침 준수 등의 특징 덕분에 일상적인 검사 건수가 감소하고 있음에도 불구하고 수요는 유지되고 있습니다. 임상 진단, 감염병 감시, 신종 호흡기 병원체에 대한 대비를 위한 지속적인 채택으로 인해 선진국 및 개발도상국의 의료 시스템 전반에서 이 부문의 지배적 지위는 더욱 공고해지고 있습니다.

용도별로는 편리하고 신속하며 자가 검사가 가능한 진단 솔루션에 대한 소비자 수요 증가를 배경으로, 예측 기간 동안 '가정 검사' 부문이 가장 빠른 성장세를 보일 것으로 전망됩니다. 신속 항원 자가 검사 키트의 보급, 재택치료에 대한 인식 제고, 소매 및 전자상거래를 통한 유통 채널의 확대가 계속해서 그 보급을 뒷받침하고 있습니다. 분산형 검사를 추진하는 정부의 이니셔티브에 더해, 사용하기 쉬운 진단 방식과 디지털 결과 보고의 발전도 시장 성장을 가속화하고 있습니다. 또한, 자가 검사는 의료시설의 부담을 줄이고 적절한 격리 조치를 신속하게 결정할 수 있게 할 뿐만 아니라, COVID-19 팬데믹 이후에도 호흡기 감염병에 대한 지속적인 모니터링을 지원합니다.

지역별 개요

2025년, 북미는 선진적인 의료 인프라, 확립된 분자진단실험실, 그리고 견고한 공중보건 감시 시스템에 힘입어 COVID-19 검출 키트 시장을 주도했습니다. 미국은 감염병 대책에 대한 지속적인 투자, RT-PCR 및 다항목 호흡기 검사의 광범위한 보급, 그리고 주요 진단 제조업체의 존재로 인해 지역별 점유율에서 가장 큰 비중을 차지했습니다. 캐나다 역시 정부가 지원하는 질병 감시 프로그램과 검사실 현대화 이니셔티브를 통해 크게 기여하고 있습니다. 일상적인 COVID-19 검사 건수는 감소하고 있지만, 호흡기 병원체 패널, 병원 내 진단, 집단 감염 대비에 대한 지속적인 수요가 이 지역의 선도적 지위를 계속 뒷받침하고 있습니다.

아시아태평양은 의료 인프라 확충, 분자진단에 대한 투자 확대, 그리고 감염병 감시 프로그램 강화에 힘입어 예측 기간 동안 가장 빠른 성장을 기록할 것으로 전망됩니다. 중국, 인도, 일본은 방대한 인구, 확대되는 진단실험실 네트워크, 신속 검사 및 분자 검사 기술의 도입 확대를 통해 주요 성장 시장으로 부상하고 있습니다. 팬데믹 대비를 강화하기 위한 정부의 이니셔티브, 진단 키트의 국내 생산 확대, 그리고 다항목 호흡기 검사가 일상적인 임상 진료에 점점 더 통합되고 있는 점이 시장 확대를 더욱 가속화하고 있습니다. 의료비 증가와 첨단 진단 기술에 대한 접근성 향상은 계속해서 이 지역 전체에 큰 성장 기회를 창출하고 있습니다.

주요 동향 및 성장 촉진요인

다항목 호흡기 진단 검사의 도입 확대 :

COVID-19 검출 키트 시장은 단일 SARS-CoV-2 검사에서 한 번의 검사로 A형·B형 인플루엔자 및 호흡기 세포융합 바이러스(RSV)를 포함한 여러 호흡기 병원체를 검출할 수 있는 다중 분자진단으로 진화하고 있습니다. 의료 제공업체와 진단 검사 기관은 임상 판단의 정확도 향상, 검사실 업무 부담 경감, 그리고 호흡기 감염병 유행기 동안의 검사 효율 향상을 도모하기 위해 이러한 솔루션의 도입을 점점 더 확대되고 있습니다. RT-PCR, 등온 증폭 및 자동화 분자진단 플랫폼의 지속적인 발전이 이러한 전환을 더욱 뒷받침하고 있습니다. 통합적인 호흡기 질환 감시 및 팬데믹 대응에 대한 관심이 높아짐에 따라, 첨단 멀티플렉스 검출 키트에 대한 수요는 앞으로도 지속될 것으로 예측됩니다.

감염병 감시 및 팬데믹 대책에 대한 투자 확대 :

정부, 의료기관, 공중보건 기관은 향후 감염병 발생에 대한 대응 능력을 강화하기 위해 감염병 감시 인프라 및 진단 체계에 대한 투자를 확대되고 있습니다. 분자진단 실험실 확충, 검사 자재의 전략적 비축, 그리고 공중보건 검사실 네트워크의 현대화가 COVID-19 검출 키트 및 관련 진단 기술에 대한 지속적인 수요를 견인하고 있습니다. 분산형 검사 도입 확대, 질병 조기 발견에 대한 인식 제고, 그리고 검사실 자동화 및 유전체 감시에 대한 지속적인 자금 지원이 시장 성장을 더욱 가속화하는 동시에 신종 감염병에 대한 장기적인 대비를 뒷받침하고 있습니다.

목차

제1장 주요 요약

제2장 시장 하이라이트

제3장 시장 역학

제4장 부문별 분석

제5장 지역별 분석

제6장 시장 전략

제7장 경쟁 정보

제8장 기업 개요

제9장 회사 소개

KTH 26.08.20

The global COVID-19 Detection Kits Market is projected to grow from $5.4 billion in 2025 to $3.4 billion by 2035, at a compound annual growth rate (CAGR) of -4.6%. The COVID-19 Detection Kits Market is moderately consolidated, with PCR-based kits accounting for the largest share due to their high diagnostic accuracy and continued use in confirmatory testing, while rapid antigen kits remain widely adopted for decentralized and point-of-care screening. Demand is increasingly supported by respiratory disease surveillance, multiplex molecular diagnostics, and preparedness for future infectious disease outbreaks. The market is characterized by continuous innovation in RT-PCR, isothermal amplification, and rapid immunoassay technologies, alongside the integration of automated laboratory workflows and digital reporting systems. Manufacturers are also expanding multiplex assays capable of detecting multiple respiratory pathogens using a single sample. For instance, in August 2025, Roche received U.S. FDA 510(k) clearance for its cobas Respiratory 4-flex molecular assay, which simultaneously detects and differentiates SARS-CoV-2, Influenza A, Influenza B, and RSV using its TAGS technology, strengthening the transition from standalone COVID-19 testing to comprehensive respiratory diagnostics and reinforcing innovation in the molecular diagnostics market.

Based on Type, the PCR-based Kits segment dominated the COVID-19 Detection Kits Market in 2025, owing to its superior diagnostic accuracy, high sensitivity, and global recognition as the reference standard for SARS-CoV-2 detection. PCR-based kits remain extensively used across hospitals, diagnostic laboratories, and public health laboratories for confirmatory diagnosis, surveillance, and variant monitoring. Their ability to detect low viral loads, support multiplex testing, and comply with regulatory guidelines has sustained demand despite declining routine testing volumes. Continuous adoption in clinical diagnostics, infectious disease surveillance, and preparedness for emerging respiratory pathogens further reinforces the segment's dominant position across developed and developing healthcare systems.

Market Segmentation
TypePCR-based Kits, Antigen-based Kits, Antibody-based Kits, Isothermal Amplification Kits, CRISPR-based Kits, Others
ProductTest Strips, Reagents, Swabs, Control Kits, Buffers, Others
TechnologyRT-PCR, LAMP, ELISA, Lateral Flow Assay, Next-Generation Sequencing, Others
ComponentSample Collection Kits, Detection Kits, Extraction Kits, Amplification Kits, Others
ApplicationClinical Testing, Home Testing, Research Laboratories, Point of Care, Screening, Others
DeploymentOn-site Testing, Remote Testing, Others
End UserHospitals, Diagnostic Laboratories, Academic and Research Institutes, Home Care, Public Health Labs, Others
ModeProfessional Use, Self-Testing, Others
StageDetection, Confirmation, Screening, Monitoring, Others

Based on Application, the Home Testing segment is expected to register the fastest growth during the forecast period, driven by increasing consumer preference for convenient, rapid, and self-administered diagnostic solutions. The widespread availability of rapid antigen self-test kits, growing awareness of home-based healthcare, and expanding retail and e-commerce distribution channels continue to support adoption. Government initiatives promoting decentralized testing, along with advancements in easy-to-use diagnostic formats and digital result reporting, are accelerating market growth. Home testing also reduces healthcare facility burden, enables timely isolation decisions, and supports ongoing monitoring of respiratory infectious diseases beyond the COVID-19 pandemic.

Geographical Overview

North America dominated the COVID-19 Detection Kits Market in 2025, supported by its advanced healthcare infrastructure, well-established molecular diagnostic laboratories, and strong public health surveillance systems. The United States accounted for the largest regional share due to continued investments in infectious disease preparedness, widespread adoption of RT-PCR and multiplex respiratory testing, and the presence of leading diagnostic manufacturers. Canada also contributes significantly through government-backed disease surveillance programs and laboratory modernization initiatives. Although routine COVID-19 testing volumes have declined, sustained demand for respiratory pathogen panels, hospital diagnostics, and outbreak preparedness continues to support the region's leadership.

Asia-Pacific is expected to register the fastest growth during the forecast period, driven by expanding healthcare infrastructure, increasing investments in molecular diagnostics, and strengthening infectious disease surveillance programs. China, India, and Japan are the key growth markets due to their large populations, expanding diagnostic laboratory networks, and rising adoption of rapid and molecular testing technologies. Government initiatives to improve pandemic preparedness, growing domestic manufacturing of diagnostic kits, and increasing integration of multiplex respiratory testing into routine clinical practice are further accelerating market expansion. Rising healthcare expenditure and improved access to advanced diagnostic technologies continue to create significant growth opportunities across the region.

Key Trends and Drivers

Increasing Adoption of Multiplex Respiratory Diagnostic Testing:

The COVID-19 detection kits market is evolving from standalone SARS-CoV-2 testing toward multiplex molecular diagnostics capable of detecting multiple respiratory pathogens, including influenza A/B and respiratory syncytial virus (RSV), through a single assay. Healthcare providers and diagnostic laboratories are increasingly adopting these solutions to improve clinical decision-making, reduce laboratory workload, and enhance testing efficiency during respiratory infection seasons. Continuous advancements in RT-PCR, isothermal amplification, and automated molecular platforms are further supporting this transition. The growing emphasis on integrated respiratory disease surveillance and pandemic preparedness is expected to sustain demand for advanced multiplex detection kits.

Growing Investments in Infectious Disease Surveillance and Pandemic Preparedness:

Governments, healthcare organizations, and public health agencies are increasing investments in infectious disease surveillance infrastructure and diagnostic preparedness to strengthen future outbreak response capabilities. The expansion of molecular diagnostic laboratories, strategic stockpiling of testing supplies, and modernization of public health laboratory networks are driving continued demand for COVID-19 detection kits and related diagnostic technologies. Rising adoption of decentralized testing, increasing awareness of early disease detection, and continuous funding for laboratory automation and genomic surveillance are further accelerating market growth while supporting long-term preparedness against emerging infectious diseases.

Research Scope

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Technology
  • 2.4 Key Market Highlights by Application
  • 2.5 Key Market Highlights by End User
  • 2.6 Key Market Highlights by Component
  • 2.7 Key Market Highlights by Mode
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Deployment

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 PCR-based Kits
    • 4.1.2 Antigen-based Kits
    • 4.1.3 Antibody-based Kits
    • 4.1.4 Isothermal Amplification Kits
    • 4.1.5 CRISPR-based Kits
    • 4.1.6 Others
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Test Strips
    • 4.2.2 Reagents
    • 4.2.3 Swabs
    • 4.2.4 Control Kits
    • 4.2.5 Buffers
    • 4.2.6 Others
  • 4.3 Market Size & Forecast by Technology (2020-2035)
    • 4.3.1 RT-PCR
    • 4.3.2 LAMP
    • 4.3.3 ELISA
    • 4.3.4 Lateral Flow Assay
    • 4.3.5 Next-Generation Sequencing
    • 4.3.6 Others
  • 4.4 Market Size & Forecast by Application (2020-2035)
    • 4.4.1 Clinical Testing
    • 4.4.2 Home Testing
    • 4.4.3 Research Laboratories
    • 4.4.4 Point of Care
    • 4.4.5 Screening
    • 4.4.6 Others
  • 4.5 Market Size & Forecast by End User (2020-2035)
    • 4.5.1 Hospitals
    • 4.5.2 Diagnostic Laboratories
    • 4.5.3 Academic and Research Institutes
    • 4.5.4 Home Care
    • 4.5.5 Public Health Labs
    • 4.5.6 Others
  • 4.6 Market Size & Forecast by Component (2020-2035)
    • 4.6.1 Sample Collection Kits
    • 4.6.2 Detection Kits
    • 4.6.3 Extraction Kits
    • 4.6.4 Amplification Kits
    • 4.6.5 Others
  • 4.7 Market Size & Forecast by Mode (2020-2035)
    • 4.7.1 Professional Use
    • 4.7.2 Self-Testing
    • 4.7.3 Others
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Detection
    • 4.8.2 Confirmation
    • 4.8.3 Screening
    • 4.8.4 Monitoring
    • 4.8.5 Others
  • 4.9 Market Size & Forecast by Deployment (2020-2035)
    • 4.9.1 On-site Testing
    • 4.9.2 Remote Testing
    • 4.9.3 Others

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Technology
      • 5.2.1.4 Application
      • 5.2.1.5 End User
      • 5.2.1.6 Component
      • 5.2.1.7 Mode
      • 5.2.1.8 Stage
      • 5.2.1.9 Deployment
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Technology
      • 5.2.2.4 Application
      • 5.2.2.5 End User
      • 5.2.2.6 Component
      • 5.2.2.7 Mode
      • 5.2.2.8 Stage
      • 5.2.2.9 Deployment
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Technology
      • 5.2.3.4 Application
      • 5.2.3.5 End User
      • 5.2.3.6 Component
      • 5.2.3.7 Mode
      • 5.2.3.8 Stage
      • 5.2.3.9 Deployment
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Technology
      • 5.3.1.4 Application
      • 5.3.1.5 End User
      • 5.3.1.6 Component
      • 5.3.1.7 Mode
      • 5.3.1.8 Stage
      • 5.3.1.9 Deployment
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Technology
      • 5.3.2.4 Application
      • 5.3.2.5 End User
      • 5.3.2.6 Component
      • 5.3.2.7 Mode
      • 5.3.2.8 Stage
      • 5.3.2.9 Deployment
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Technology
      • 5.3.3.4 Application
      • 5.3.3.5 End User
      • 5.3.3.6 Component
      • 5.3.3.7 Mode
      • 5.3.3.8 Stage
      • 5.3.3.9 Deployment
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Technology
      • 5.4.1.4 Application
      • 5.4.1.5 End User
      • 5.4.1.6 Component
      • 5.4.1.7 Mode
      • 5.4.1.8 Stage
      • 5.4.1.9 Deployment
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Technology
      • 5.4.2.4 Application
      • 5.4.2.5 End User
      • 5.4.2.6 Component
      • 5.4.2.7 Mode
      • 5.4.2.8 Stage
      • 5.4.2.9 Deployment
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Technology
      • 5.4.3.4 Application
      • 5.4.3.5 End User
      • 5.4.3.6 Component
      • 5.4.3.7 Mode
      • 5.4.3.8 Stage
      • 5.4.3.9 Deployment
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Technology
      • 5.4.4.4 Application
      • 5.4.4.5 End User
      • 5.4.4.6 Component
      • 5.4.4.7 Mode
      • 5.4.4.8 Stage
      • 5.4.4.9 Deployment
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Technology
      • 5.4.5.4 Application
      • 5.4.5.5 End User
      • 5.4.5.6 Component
      • 5.4.5.7 Mode
      • 5.4.5.8 Stage
      • 5.4.5.9 Deployment
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Technology
      • 5.4.6.4 Application
      • 5.4.6.5 End User
      • 5.4.6.6 Component
      • 5.4.6.7 Mode
      • 5.4.6.8 Stage
      • 5.4.6.9 Deployment
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Technology
      • 5.4.7.4 Application
      • 5.4.7.5 End User
      • 5.4.7.6 Component
      • 5.4.7.7 Mode
      • 5.4.7.8 Stage
      • 5.4.7.9 Deployment
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Technology
      • 5.5.1.4 Application
      • 5.5.1.5 End User
      • 5.5.1.6 Component
      • 5.5.1.7 Mode
      • 5.5.1.8 Stage
      • 5.5.1.9 Deployment
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Technology
      • 5.5.2.4 Application
      • 5.5.2.5 End User
      • 5.5.2.6 Component
      • 5.5.2.7 Mode
      • 5.5.2.8 Stage
      • 5.5.2.9 Deployment
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Technology
      • 5.5.3.4 Application
      • 5.5.3.5 End User
      • 5.5.3.6 Component
      • 5.5.3.7 Mode
      • 5.5.3.8 Stage
      • 5.5.3.9 Deployment
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Technology
      • 5.5.4.4 Application
      • 5.5.4.5 End User
      • 5.5.4.6 Component
      • 5.5.4.7 Mode
      • 5.5.4.8 Stage
      • 5.5.4.9 Deployment
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Technology
      • 5.5.5.4 Application
      • 5.5.5.5 End User
      • 5.5.5.6 Component
      • 5.5.5.7 Mode
      • 5.5.5.8 Stage
      • 5.5.5.9 Deployment
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Technology
      • 5.5.6.4 Application
      • 5.5.6.5 End User
      • 5.5.6.6 Component
      • 5.5.6.7 Mode
      • 5.5.6.8 Stage
      • 5.5.6.9 Deployment
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Technology
      • 5.6.1.4 Application
      • 5.6.1.5 End User
      • 5.6.1.6 Component
      • 5.6.1.7 Mode
      • 5.6.1.8 Stage
      • 5.6.1.9 Deployment
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Technology
      • 5.6.2.4 Application
      • 5.6.2.5 End User
      • 5.6.2.6 Component
      • 5.6.2.7 Mode
      • 5.6.2.8 Stage
      • 5.6.2.9 Deployment
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Technology
      • 5.6.3.4 Application
      • 5.6.3.5 End User
      • 5.6.3.6 Component
      • 5.6.3.7 Mode
      • 5.6.3.8 Stage
      • 5.6.3.9 Deployment
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Technology
      • 5.6.4.4 Application
      • 5.6.4.5 End User
      • 5.6.4.6 Component
      • 5.6.4.7 Mode
      • 5.6.4.8 Stage
      • 5.6.4.9 Deployment
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Technology
      • 5.6.5.4 Application
      • 5.6.5.5 End User
      • 5.6.5.6 Component
      • 5.6.5.7 Mode
      • 5.6.5.8 Stage
      • 5.6.5.9 Deployment

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Roche Diagnostics
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Abbott Laboratories
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Thermo Fisher Scientific
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Siemens Healthineers
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Becton Dickinson
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Bio-Rad Laboratories
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Qiagen
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Hologic
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 PerkinElmer
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Danaher Corporation
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 bioMerieux
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Cepheid
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Luminex Corporation
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Quidel Corporation
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 GenMark Diagnostics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 OraSure Technologies
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 F. Hoffmann-La Roche
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Meridian Bioscience
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Seegene
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Tecan Group
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제
문의
원하시는 정보를
찾아 드릴까요?
문의주시면 필요한 정보를
신속하게 찾아드릴게요.
02-2025-2992
email
문의하기